Index‐based dietary patterns and risk of incident hepatocellular carcinoma and mortality from chronic liver disease in a prospective study

Wen‐Qing Li, Yikyung Park, Katherine A. McGlynn, Albert R. Hollenbeck, Philip R. Taylor, Alisa M. Goldstein, Neal D. Freedman – 9 April 2014 – The role of diet in hepatocellular carcinoma (HCC) and its typical precursor, chronic liver disease (CLD), is poorly understood. Following dietary recommendations has been shown to reduce risk of many cancers, but whether such diets are associated with HCC and CLD is unknown.

Binding of hepatitis B virus to its cellular receptor alters the expression profile of genes of bile acid metabolism

Nicola Oehler, Tassilo Volz, Oliver D. Bhadra, Janine Kah, Lena Allweiss, Katja Giersch, Jeanette Bierwolf, Kristoffer Riecken, Jörg M. Pollok, Ansgar W. Lohse, Boris Fehse, Joerg Petersen, Stephan Urban, Marc Lütgehetmann, Joerg Heeren, Maura Dandri – 8 April 2014 – Chronic hepatitis B virus (HBV) infection has been associated with alterations in lipid metabolism. Moreover, the Na+‐taurocholate cotransporting polypeptide (NTCP), responsible for bile acid (BA) uptake into hepatocytes, was identified as the functional cellular receptor mediating HBV entry.

Patient‐reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir‐containing regimens

Zobair M. Younossi, Maria Stepanova, Fatema Nader, Ira M. Jacobson, Ed Gane, David Nelson, Eric Lawitz, Sharon L. Hunt – 8 April 2014 – Whether the presence of cirrhosis influences patient‐reported outcomes (PROs), including health‐related quality of life, during treatment with newly available anti‐HCV (hepatitis C virus) regimens is unclear. Our aim was to assess the association of cirrhosis with PROs in patients treated with sofosbuvir (SOF)‐containing regimens.

Caveolin‐1 is essential for protecting against binge drinking‐induced liver damage through inhibiting reactive nitrogen species

Lei Gao, Yingchun Zhou, Weichao Zhong, Xiaohua Zhao, Chun Chen, Xingmiao Chen, Yong Gu, Jianping Chen, Zhiping Lv, Jiangang Shen – 8 April 2014 – Caveolin‐1 (Cav‐1) is known to participate in many diseases, but its roles in alcoholic liver injury remain unknown. In the present study, we aimed to explore the roles of Cav‐1 in protecting hepatocytes from ethanol‐mediated nitrosative injury.

Perioperative complications in liver transplantation using donation after cardiac death grafts: A propensity‐matched study

Xiongxiong Pan, Worapot Apinyachon, Wei Xia, Johnny C. Hong, Ronald W. Busuttil, Randolph H. Steadman, Victor W. Xia – 8 April 2014 – Donation after cardiac death (DCD) is an important source for expanding the donor pool for liver transplantation (LT). Although the long‐term outcomes of LT using DCD grafts have been extensively studied, perioperative complications related to DCD grafts are rarely reported. The aim of this study was to determine whether DCD grafts were associated with a higher incidence of postreperfusion complications and worse outcomes in adult LT patients.

New‐onset cognitive dysfunction impairs the quality of life in patients after liver transplantation

Anita Blanka Tryc, Henning Pflugrad, Annemarie Goldbecker, Hannelore Barg‐Hock, Christian P. Strassburg, Hartmut Hecker, Karin Weissenborn – 8 April 2014 – Patients after orthotopic liver transplantation (OLT) may show cognitive dysfunction. To date, it has not been clear whether this dysfunction is due to residual hepatic encephalopathy (HE) or new‐onset cognitive disturbances. Just as little is known about the course and clinical significance.

Pilot test of a patient decision aid about liver transplant organ quality

Michael L. Volk, Meghan Roney, Angela Fagerlin – 7 April 2014 – Prior studies have shown that patients are reluctant to accept donor‐specific risks, and transplant professionals lack an effective and time‐efficient means of obtaining informed consent. We designed and pilot‐tested a Web‐based patient decision aid (DA) on organ quality. The DA was administered to 53 liver transplant candidates (median Model for End‐Stage Liver Disease score = 14, range = 7‐26), and they took a mean of 15 minutes to complete it. Questions about knowledge and attitudes were asked before and after the DA.

Reversal of hepatocyte senescence after continuous in vivo cell proliferation

Min‐Jun Wang, Fei Chen, Jian‐Xiu Li, Chang‐Cheng Liu, Hai‐Bin Zhang, Yong Xia, Bing Yu, Pu You, Dao Xiang, Lian Lu, Hao Yao, Uyunbilig Borjigin, Guang‐Shun Yang, Kirk J. Wangensteen, Zhi‐Ying He, Xin Wang, Yi‐Ping Hu – 7 April 2014 – A better understanding of hepatocyte senescence could be used to treat age‐dependent disease processes of the liver. Whether continuously proliferating hepatocytes could avoid or reverse senescence has not yet been fully elucidated.

Subscribe to